Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The C4 Therapeutics, Inc. (CCCC) SEC filings page on Stock Titan provides structured access to the companys regulatory disclosures as filed with the U.S. Securities and Exchange Commission. C4 Therapeutics is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detail on clinical progress, collaborations, financings and corporate governance related to its targeted protein degradation programs.
Investors can use this page to review Form 8-K current reports in which C4 Therapeutics furnishes quarterly financial results, business highlights and updates on key clinical programs such as cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and non-Hodgkins lymphoma. 8-K filings also document material events including the clinical trial collaboration and supply agreement with Pfizer for elranatamab, underwritten equity offerings involving common stock and warrants, and stockholder approvals to increase authorized shares.
In addition to event-driven 8-Ks, the companys shelf registration statements, prospectus supplements and related exhibits describe the terms of securities offerings used to fund its pipeline, including cemsidomide, CFT8919 and other degrader programs. Governance-related filings, such as amendments to the certificate of incorporation and annual meeting voting results, provide insight into C4 Therapeutics capital structure and board-level decisions.
On Stock Titan, these SEC documents are complemented by AI-powered summaries that highlight the most important points in each filing, helping readers quickly understand topics like new clinical data disclosures, changes in collaboration arrangements, or the impact of financings on cash runway. Users interested in CCCC can consult this page to follow how C4 Therapeutics reports its clinical, financial and corporate developments through official SEC channels over time.